Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Purinergic signalling

Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V.
PMID: 34347213
Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04.

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an...

Cite
Janho Dit Hreich S, Benzaquen J, Hofman P, et al. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021;17(4):619-631doi: 10.1007/s11302-021-09811-9.
Janho Dit Hreich, S., Benzaquen, J., Hofman, P., & Vouret-Craviari, V. (2021). To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic signalling, 17(4), 619-631. https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich, Serena, et al. "To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question." Purinergic signalling vol. 17,4 (2021): 619-631. doi: https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04. PMID: 34347213.
Copy Download .nbib Format: NLM
To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Purinergic signalling

Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V.
PMID: 34347213
Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04.

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an...

Cite
Janho Dit Hreich S, Benzaquen J, Hofman P, et al. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021;17(4):619-631doi: 10.1007/s11302-021-09811-9.
Janho Dit Hreich, S., Benzaquen, J., Hofman, P., & Vouret-Craviari, V. (2021). To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic signalling, 17(4), 619-631. https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich, Serena, et al. "To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question." Purinergic signalling vol. 17,4 (2021): 619-631. doi: https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04. PMID: 34347213.
Copy Download .nbib Format: NLM
To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Purinergic signalling

Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V.
PMID: 34347213
Purinergic Signal. 2021 Aug 04; doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04.

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an...

Cite
Janho Dit Hreich S, Benzaquen J, Hofman P, et al. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021;doi: 10.1007/s11302-021-09811-9.
Janho Dit Hreich, S., Benzaquen, J., Hofman, P., & Vouret-Craviari, V. (2021). To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic signalling, . https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich, Serena, et al. "To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question." Purinergic signalling vol. (2021). doi: https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021 Aug 04; doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04. PMID: 34347213.
Copy Download .nbib Format: NLM
To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Purinergic signalling

Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V.
PMID: 34347213
Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04.

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an...

Cite
Janho Dit Hreich S, Benzaquen J, Hofman P, et al. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021;17(4):619-631doi: 10.1007/s11302-021-09811-9.
Janho Dit Hreich, S., Benzaquen, J., Hofman, P., & Vouret-Craviari, V. (2021). To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic signalling, 17(4), 619-631. https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich, Serena, et al. "To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question." Purinergic signalling vol. 17,4 (2021): 619-631. doi: https://doi.org/10.1007/s11302-021-09811-9
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V. To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal. 2021 Dec;17(4):619-631. doi: 10.1007/s11302-021-09811-9. Epub 2021 Aug 04. PMID: 34347213; PMCID: PMC8677881.
Copy Download .nbib Format: NLM
MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma.

Oncotarget

Bozec A, Zangari J, Butori-Pepino M, Ilie M, Lalvee S, Juhel T, Butori C, Brest P, Hofman P, Vouret-Craviari V.
PMID: 28915663
Oncotarget. 2017 Jul 11;8(34):57174-57186. doi: 10.18632/oncotarget.19170. eCollection 2017 Aug 22.

MicroRNAs (miRs) participate in tumor growth and dissemination by regulating expression of various target genes. MiR-223-3p is suspected of being involved in head and neck squamous cell carcinoma (HNSCC) growth although its precise role has not been elucidated. In...

Cite
Bozec A, Zangari J, Butori-Pepino M, et al. MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. Oncotarget. 2017;8(34):57174-57186doi: 10.18632/oncotarget.19170.
Bozec, A., Zangari, J., Butori-Pepino, M., Ilie, M., Lalvee, S., Juhel, T., Butori, C., Brest, P., Hofman, P., & Vouret-Craviari, V. (2017). MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. Oncotarget, 8(34), 57174-57186. https://doi.org/10.18632/oncotarget.19170
Bozec, Alexandre, et al. "MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma." Oncotarget vol. 8,34 (2017): 57174-57186. doi: https://doi.org/10.18632/oncotarget.19170
Bozec A, Zangari J, Butori-Pepino M, Ilie M, Lalvee S, Juhel T, Butori C, Brest P, Hofman P, Vouret-Craviari V. MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. Oncotarget. 2017 Jul 11;8(34):57174-57186. doi: 10.18632/oncotarget.19170. eCollection 2017 Aug 22. PMID: 28915663; PMCID: PMC5593634.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries